Fresenius Kabi

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Subsidiary

Established: 1999-01-01

Employees: -

Market Cap: -

Website: http://www.fresenius-kabi.com

Clinical Trials

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Phase 4

Recruiting

Conditions: Parenteral Nutrition Associated Liver Disease (PNALD)
Essential Fatty Acid Deficiency
Malnutrition
Pediatric ALL

Interventions: Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion

First Posted Date: 2024-02-23

Last Posted Date: 2024-11-27

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 40

Registration Number: NCT06274788

Locations: 🇺🇸
Memorial Health Service, Fountain Valley, California, United States
🇺🇸
Board of Regents of the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸
Baylor College of Medicine Houston, Houston, Texas, United States

and more 1 locations

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

Phase 4

Recruiting

Conditions: Malnutrition, Child
Malnutrition
Essential Fatty Acid Deficiency (EFAD)
Parenteral Nutrition Associated Cholestasis

Interventions: Drug: SMOFlipid® (lipid injectable emulsion)

First Posted Date: 2023-09-22

Last Posted Date: 2024-11-29

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 100

Registration Number: NCT06049680

Locations: 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care

Phase 3

Completed

Conditions: Nutrition Therapy
Critical Illness

Interventions: Drug: SmofKabiven extra Nitrogen

First Posted Date: 2022-02-25

Last Posted Date: 2024-02-21

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 56

Registration Number: NCT05257031

Locations: 🇷🇺
Municipal Clinical Hospital No. 40 of Moscow Healthcare Department, Moscow, Russian Federation

bIosimilar of aDalimumab, an European evAluation

Conditions: Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Crohn Disease

First Posted Date: 2022-01-13

Last Posted Date: 2022-01-13

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 1050

Registration Number: NCT05190484

A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response

Completed

Conditions: Ankylosing Spondylitis
Ulcerative Colitis
Psoriatic Arthritis
Crohn Disease
Rheumatoid Arthritis
Psoriasis

First Posted Date: 2021-09-21

Last Posted Date: 2023-07-19

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 754

Registration Number: NCT05051943

Locations: 🇫🇷
CHRU de Nancy - Hôpitaux de Brabois, Vandœuvre-lès-Nancy, France

Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)

Withdrawn

Conditions: Neurocognitive Deficit
Essential Fatty Acid Deficiency
Parenteral Nutrition Associated Liver Disease
Malnutrition
Pediatric ALL

Interventions: Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion

First Posted Date: 2021-03-19

Last Posted Date: 2022-08-04

Lead Sponsor: Fresenius Kabi

Registration Number: NCT04807478

Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critically Ill Patients

Completed

Conditions: Critical Illness

First Posted Date: 2019-10-29

Last Posted Date: 2020-07-31

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 1208

Registration Number: NCT04143503

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria
🇧🇪
Universitair Ziekenhuis Brussel, Brussels, Belgium
🇧🇪
Clinique Universitaire Saint-Luc - Université Catholique de Louvain (UCL), Brussels, Belgium

and more 73 locations

Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness

Phase 4

Terminated

Conditions: Critical Illness

Interventions: Drug: SmofKabiven® extra Nitrogen
Drug: Olimel N9E

First Posted Date: 2019-06-20

Last Posted Date: 2020-10-14

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 7

Registration Number: NCT03992716

Locations: 🇫🇷
Hôpital Saint-Antoine, Département d'Anesthésie-Réanimation, Paris, France
🇩🇪
Klinikum rechts der Isar, Klinik für Anaesthesiologie, München, Germany
🇵🇱
SP ZOZ Wojewódzki Szpital Zespolony im. J. Śniadeckiego, Białystok, Poland

Efficacy & Safety of SmofKabiven Emulsion for Infusion vs Hospital Compounded "All in One" for Parenteral Nutrition

Phase 3

Completed

Conditions: Parenteral Nutrition
Surgery

Interventions: Drug: SmofKabiven emulsion for infusion
Drug: Hospital compounded "All in one" emulsion

First Posted Date: 2019-01-03

Last Posted Date: 2021-08-02

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 273

Registration Number: NCT03792100

Locations: 🇨🇳
The Second Hospital of Jilin University, Changchun, China
🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China
🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

and more 5 locations

Efficacy and Safety of SmofKabiven Peripheral Versus Compounded Emulsion

Phase 3

Completed

Conditions: Parenteral Feeding
Surgery

Interventions: Drug: SmofKabiven Peripheral
Drug: Hospital compounded emulsion

First Posted Date: 2019-01-03

Last Posted Date: 2021-08-02

Lead Sponsor: Fresenius Kabi

Target Recruit Count: 272

Registration Number: NCT03792087

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China
🇨🇳
Beijing Friendship Hospital Capital Medical University, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, China

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy